DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis
Charles E. Mowbray, Stéphanie Braillard, Paul A. Glossop, Gavin A. Whitlock, Robert T. Jacobs, Jason D. Speake, Bharathi Pandi, Bakela Nare, Louis Maes, Vanessa Yardley, Yvonne R. Freund, Richard J. Wall, Sandra Carvalho, Davide Bello, Magali Van den Kerkhof, Guy Caljon, Ian H. Gilbert, Victoriano Corpas‐López, Iva Lukač, Stephen Patterson, Fabio Zuccotto, Susan Wyllie
Abstract
cleavage and polyadenylation specificity factor (CPSF3) endonuclease. As a result of these studies and its promising profile, DNDI-6148 has been declared a preclinical candidate for the treatment of VL.
Topics & Concepts
Visceral leishmaniasisLeishmaniasisIn vivoPharmacologyTropical diseaseLeishmania donovaniNeglected tropical diseasesParasitic diseaseDiseaseMedicineImmunologyBiologyInternal medicineBiotechnologyResearch on Leishmaniasis StudiesTrypanosoma species research and implicationsSynthesis and Biological Evaluation